CN105969700B - A kind of lactobacillus plantarum and its application with absorption manganese ion function - Google Patents
A kind of lactobacillus plantarum and its application with absorption manganese ion function Download PDFInfo
- Publication number
- CN105969700B CN105969700B CN201610562884.9A CN201610562884A CN105969700B CN 105969700 B CN105969700 B CN 105969700B CN 201610562884 A CN201610562884 A CN 201610562884A CN 105969700 B CN105969700 B CN 105969700B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- manganese
- ccfm436
- preparation
- application according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 68
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 66
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 66
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical group [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 title abstract description 34
- 238000010521 absorption reaction Methods 0.000 title abstract description 6
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 39
- 235000021107 fermented food Nutrition 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 11
- 239000003223 protective agent Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000004321 preservation Methods 0.000 claims description 7
- 235000020183 skimmed milk Nutrition 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229940039696 lactobacillus Drugs 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 239000002068 microbial inoculum Substances 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 229940041514 candida albicans extract Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 3
- 229940073490 sodium glutamate Drugs 0.000 claims description 3
- 239000012137 tryptone Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000012138 yeast extract Substances 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000002906 microbiologic effect Effects 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000011572 manganese Substances 0.000 abstract description 38
- 229910052748 manganese Inorganic materials 0.000 abstract description 37
- 229910001437 manganese ion Inorganic materials 0.000 abstract description 30
- 238000001179 sorption measurement Methods 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 238000004088 simulation Methods 0.000 description 10
- 239000000470 constituent Substances 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000005903 Manganese Poisoning Diseases 0.000 description 5
- 206010027439 Metal poisoning Diseases 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 235000013322 soy milk Nutrition 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 3
- 230000005526 G1 to G0 transition Effects 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000020167 acidified milk Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000003188 neurobehavioral effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 239000002893 slag Substances 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000028571 Occupational disease Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000006079 antiknock agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229950009719 calcium trisodium pentetate Drugs 0.000 description 1
- AYFCVLSUPGCQKD-UHFFFAOYSA-I calcium;trisodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O AYFCVLSUPGCQKD-UHFFFAOYSA-I 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 239000003500 flue dust Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- -1 manganese inorganic compound Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 231100000754 permissible exposure limit Toxicity 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GMUQJDAYXZXBOT-UHFFFAOYSA-M sodium;4-amino-2-hydroxybenzoate;dihydrate Chemical compound O.O.[Na+].NC1=CC=C(C([O-])=O)C(O)=C1 GMUQJDAYXZXBOT-UHFFFAOYSA-M 0.000 description 1
- BCWRXLLYMXFJDY-UHFFFAOYSA-M sodium;4-hydroxy-4-oxo-2,3-bis(sulfanyl)butanoate Chemical compound [Na+].OC(=O)C(S)C(S)C([O-])=O BCWRXLLYMXFJDY-UHFFFAOYSA-M 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009923 sugaring Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C20/00—Cheese substitutes
- A23C20/02—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates
- A23C20/025—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates mainly containing proteins from pulses or oilseeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a kind of lactobacillus plantarum with absorption manganese ion function and its applications, belong to microorganisms technical field.Lactobacillus plantarum CCFM436 of the invention has good tolerance and adsorption capacity to manganese ion in vitro, and the content of manganese ion in manganese containing solution can be effectively reduced.The lactobacillus plantarum CCFM436 is used to prepare pharmaceutical composition and fermented food with row's manganese function, is with a wide range of applications.
Description
Technical field
The present invention relates to a kind of lactobacillus plantarum with absorption manganese ion function and its applications, belong to microbial technique neck
Domain.
Background technique
Manganese is one of element needed by human, is constituent, activity factor or the confactor of a variety of enzymes of cell, in body
Inside exist in the form of an ion, is mainly distributed in the tissue and organ rich in mitochondria.Under normal circumstances, the manganese that human body is absorbed
It is absorbed in enteron aisle.However, manganese is a kind of common environment and professional pollutant at present, respiratory tract, alimentary canal etc. can be passed through
Approach enters human body and accumulates and generate ill-effect.Manganese flue dust as defined in (OSHA) is affixed one's name in U.S.'s employment security and sanitary administration at present
Permissible exposure limit be 5mg/m3, the threshold limit value of manganese element and manganese inorganic compound that American industry hygienist's meeting is formulated
It (TLV) is 0.2mg/m3, and the manganese exposure limit that National Institute and sanitation association are recommended is 1mg/m3.China is rich in manganese ore,
Widely distributed, Xiushan, Chongqing county, Huayuan, Hunan county and Guizhou Song Taoxian are referred to as " manganese triangle " area.With opening for mineral resources
Being continuously increased for smelting, the discharge of slag and effluent and Abandoned Land of Mine is adopted, so that the manganese content of multiple cross section of rivers severely exceeds,
Environmental pollution is serious.In China, the generation number of professional Chronic Mn Poisoning has occupied first five position of report occupational disease, and manganese exposure
Significant change occurs for the neurobehavioral for having resulted in pollution by manganese area children.Although country takes special administration to arrange pollution by manganese
It applies, but the accumulation of a large amount of manganese slags thrown aside with river bed, so that pollution by manganese, which is administered, becomes a difficult task for a long time.In addition,
Successively using methyl cyclopentyl-dialkyl-tricarbon manganium as gasoline anti-knock agent, ethylidene dithiocarbamate manganese is as sterilization
Agent increases the chance of human contact's manganese so that manganese be made to rapidly diffuse into environment, thus the potential danger for increasing manganese poisoning
Property.
The probability that manganese is enriched in animals and plants and human body significantly increases, and manganese poisoning has caused people's extensive concern.It is excessive
After manganese enters human body, toxic effect is all had to a variety of organs such as nerve, liver, reproduction, immune and angiocarpy and system.Wherein
Nervous system is the target organ of manganese toxicity.Compared with other organs, poisonous effect caused by intake of the brain for Excessive Manganese is the most
Sensitivity, excessive manganese can cause central nervous system exception and neurobehavioral disorder in the savings of brain.Manganese poisoning early stage is with mind
Based on asthenic syndrome and vegetative nerve functional disturbance, advanced stage may occur in which that outside apparent centrum be nerve damage symptom, such as dynamic
It trembles as property, is bradykinesia, muscular rigidity, dystonia and gait disorder etc..Manganese to mitochondria have very strong affinity, two
Valence manganese ion can enter mitochondria by calcium transport body.A large amount of manganese can mutually be tied in mitochondria with mitochondrial membrane or stromatin
It closes, allows manganese that directly effect occurs with oxidative phosphorylation GAP-associated protein GAP.Manganese can not influence other enzyme activity of electron transport chain
Property on the basis of, directly inhibit adenosine triphosphate synthetase activity, to inhibit the generation of ATP.In addition, manganese appropriate is in life
It can promote body fight free-radical oxidation in object, but excessive manganese can be promoted by active cell chromo-oxidase p450 activity
Free radical is generated, sulfydryl is caused to be exhausted, cellular anti-oxidant capacity decline, induced oxidation stress reaction occurs.
For the various physiological conditions as caused by manganese poisoning, calcium disodium edetate, calcium trisodium pentetate, sodium dimercaptosuccinate are generallyd use
Or the chelating agents such as paramisan sodium carry out oral or inject treatment, to reduce the concentration of in-vivo metal ion.However, these
All there is certain side effect, calcium disodium edetate can chelate with a variety of divalent, trivalent metal ion, be formed and stablized drug
Metal complex, through kidney with urine exclude, to kidney have stronger toxicity.And micro member can be caused when taking drugs
The reduction of element, especially Zn-ef ficiency.Therefore a large amount of or long-term use calcium disodium edetate can jeopardize the health of people.Two mercapto fourths
Disodium drug can cause halitosis, pain, nausea, the out of strength and reaction such as have aches in the limbs, and also have certain side effect to human body.
In view of problems existing for traditional therapy, it is aobvious that a kind of new intervention or treatment method are found for manganese poisoning
It obtains very necessary.Lactic acid bacteria is advantage normal flora in animal intestinal tract, is generally acknowledged safe probiotics, is widely present in nature hair
Kefir milk product, human intestine and fermenting plant food such as sauerkraut, pickles etc..Long-Term Scientific Study the result shows that, with lactic acid
Bacterium is that the probiotics of representative is that human body is essential and beneficial bacterium with important physiological function, and major function has: can be extensive
The balance of multiple human body intestinal canal flora safeguards human health, can prevent and treat lactose intolerance, controllable toxins in human body level, can protect
Protect liver is dirty and enhances the function of detoxification etc. of liver.Microorganism of the lactic acid bacteria as a kind of food-grade, without metal-chelator
Serious side effects.Therefore the effect for exploring probiotics alleviation manganese poisonous effect can further excavate the function of probiotics, exploitation
Probiotics with higher health value hews out new solution and approach to alleviate manganese toxicity using diet strategy.
Summary of the invention
The first purpose of the invention is to provide a kind of lactobacillus plantarum Lactobacillus plantarum, in 2016
Was preserved in China Microbial Culture Preservation Commission common micro-organisms center CGMCC on May 23, and preservation address is Beijing
No. 3 Institute of Microorganism, Academia Sinica, institute of Chaoyang District Beichen Lu 1, deposit number are CGMCC No.12470, are named as plant
Lactobacillus CCFM436.
The lactobacillus plantarum CGMCC No.12470 has following biological characteristics:
(1) acid resistance, the well-grown under pH3.0-9.0 environmental condition are survived good under pH2.5 environment；
(2) minimum growth temperature is 18 DEG C, and maximum growth temperature is 40 DEG C, and best, the most suitable growth is grown at 30-37 DEG C
Initial pH value is 6.0；The period of delay of lactobacillus plantarum strain of the present invention is relatively short, and 4h or so enters logarithmic phase, and 12h reaches steady
Periodically.
(3) it can grow, have to manganese ion fine in the MRS culture medium containing 960mg/L~5760mg/L manganese ion
Tolerance；
(4) be incubated in solution containing manganese ion in vitro, to manganese ion have good adsorption capacity, manganese containing 50mg/L from
In the manganese solution of son, the clearance rate to manganese ion is 24.34%.
(5) it is incubated in simulation stomach and intestine liquor, there is preferable tolerance to simulation gastro-intestinal Fluid, incubated in simulate the gastric juice
The survival rate for educating 2h is 92.18%, and the survival rate that 5h is incubated in simulated intestinal fluid is 91.64%.
A second object of the present invention is to provide the drugs that manganese toxicity is alleviated in application lactobacillus plantarum CCFM436 preparation
The method of composition.Described pharmaceutical composition is by lactobacillus plantarum CCFM436 microbial inoculum and pharmaceutically acceptable vehicle group
At.
The pharmaceutically acceptable carrier be pharmaceutically allow using filler, adhesive, wetting agent, disintegrating agent,
One of lubricant or corrigent or its two or more combination.
The pharmaceutically acceptable carrier be pharmaceutically allow using filler, adhesive, wetting agent, disintegration
One of agent, lubricant or corrigent or its two or more combination.
The pharmaceutical composition includes granule, capsule, tablet, pill and oral solutions.
The lactobacillus plantarum CCFM436 microbial inoculum is to be prepared into the bacterium solution containing the lactobacillus plantarum CCFM436
Bacterium powder, makes it contain 106The active plant lactobacillus CCFM436 of CFU/g or more.
In one embodiment of the invention, the lactobacillus plantarum CCFM436 microbial inoculum is by being freeze-dried work
The pulvis that skill is prepared, contains 106The active plant lactobacillus CCFM436 of CFU/g or more.
A second object of the present invention is to provide the methods that the lactobacillus plantarum CCFM436 prepares fermented food.
The fermented food is dairy products, the beans produced using the leavening containing the lactobacillus plantarum CCFM436
Product and fruit and vegetable product.
In one embodiment of the invention, the leavening preparation the following steps are included:
(1) preparation of culture medium: use in terms of culture medium gross mass 87.7% water by 10% enzyme hydrolysis skimmed milk,
0.5% glucose, 1.5% tryptone and the dissolution of 0.3% yeast extract, then adjusting its pH value is 6.4, obtains culture medium；
(2) protectant preparation: protective agent system gross mass meter pastes 10% skimmed milk power, 3% glycerol, 10% malt ring
Essence, 15% trehalose, 1%L- sodium glutamate and water are mixed with protective agent；
(3) lactobacillus plantarum CCFM436 is inoculated into the cooling culture of a sterilizing by the inoculum concentration of the 2-5% of culture medium quality
In base, then the stationary culture 18h at 37 DEG C, is cleaned 2-4 times with the phosphate buffer of pH7.2, and the protective agent is added
Thallus is resuspended, cell concentration is made to reach 1010CFU/mL；Again by bacteria suspension at 37 DEG C with culture 60min, freeze-drying obtain institute
The fermenting agent stated.
The utility model has the advantages that lactobacillus plantarum CCFM436 of the invention has good adsorption capacity and tolerance to manganese ion,
And there is good tolerance effect in simulation gastro-intestinal Fluid, lay the foundation further to excavate the function of lactic acid bacteria, exploitation tool
There is the lactic acid bacteria of higher value.The lactobacillus plantarum CCFM436 can be used for preparing the pharmaceutical composition for alleviating manganese toxicity kinetic energy
With fermented food, there is very extensive application prospect.
Biomaterial preservation
Lactobacillus plantarum Lactobacillus plantarum was preserved in China Microbiological bacterium on May 23rd, 2016
Kind preservation committee common micro-organisms center CGMCC, preservation address are No. 3 Chinese sciences of the institute of Chaoyang District, Beijing City Beichen Lu 1
Institute of microbiology, institute, deposit number are CGMCC No.12470.
Detailed description of the invention
Fig. 1 is suction-operated of the lactobacillus plantarum CCFM436 to manganese ion；
Fig. 2 is lactobacillus plantarum CCFM436 growth curve in the MRS culture medium containing manganese ion；
Fig. 3 is the cell electron microscope that lactobacillus plantarum CCFM436 is grown in the MRS culture medium containing manganese ion；A,
16mg/L manganese ion；B, 960mg/L manganese ion；C, 5760mg/L manganese ion；Scale is 1 μm.
Specific embodiment
Suction-operated of the 1 lactobacillus plantarum CCFM436 of embodiment to manganese ion
Lactobacillus plantarum CCFM436 is incubated in the aqueous solution containing manganese ion in vitro, verifies its absorption to manganese ion
Ability.Lactobacillus plantarum CCFM436 is transferred in the manganese solution of the manganese ion containing 50mg/L and 100mg/L, keeps plant newborn
Bacillus CCFM436 ultimate density reaches 1g/L.By the sample containing lactobacillus plantarum CCFM436 at 37 DEG C oscillation incubation 1h,
6000rpm is centrifuged 10min, then is centrifuged once with sterile water washing, is separated off supernatant.Pure nitre is added into obtained thallus
Acid is put into Hyperfrequency waves eliminating stove and clears up 20min, and obtained digestion solution is contained using atomic absorption spectrometer measurement manganese ion
Amount, to determine bacterial strain to the adsorption capacity of manganese ion.
The result shows that (Fig. 1) lactobacillus plantarum CCFM436 is to the clearance rate of the manganese ion of the manganese solution of 50mg/L
24.34%, the clearance rate to the manganese ion of the manganese solution of 100mg/L is 15.86%, and lactobacillus plantarum CCFM436 is shown pair
Manganese ion has good adsorption capacity and Scavenging activity.
2 lactobacillus plantarum CCFM436 of embodiment is to manganese ion tolerance
Aseptically, 17.70g MnSO is separately added into 1L sterile MRS fluid nutrient medium4·H2O and 2.95g
MnSO4·H2O, (manganese ion respectively containing 5760mg/L and 960mg/L), membrane filtration degerming.
Will the lactobacillus plantarum CCFM436 that growth stationary phase be entered be inoculated in by 2% inoculum concentration it is above-mentioned containing manganese ion
MRS fluid nutrient medium in, static gas wave refrigerator 18h is carried out at 37 DEG C, period sampling measuring OD value simultaneously draws thalli growth curve.
It can be seen from attached drawing 2 under the manganese ion concentration of 960mg/L and 5760mg/L, lactobacillus plantarum CCFM436 is equal
Can normal growth, stationary phase OD6004.0 or more can be reached.
Through Electronic Speculum observation of plant lactobacillus CGMCC No.12470 in the culture medium containing various concentration manganese ion
Thalli morphology.It can be seen from attached drawing 3 under the manganese ion concentration of 960mg/L and 5760mg/L, lactobacillus plantarum CGMCC
No.12470 thalli morphology can keep complete.
Tolerance test of the 3 lactobacillus plantarum CCFM436 of embodiment to simulate the gastric juice
The preparation of artificial simulation gastric juices: 6.2g/LNaCl, 2.2g/LKCl, 0.22g/L CaCl2, 1.2g/LNaHCO3,
0.3% pepsin, pH 3.0.
The lactobacillus plantarum CCFM436 of growth stationary phase will be entered in MRS culture medium culture, with the phosphorus of the pH7.2 of 1.0mL
Phthalate buffer cleaning thallus twice, then with the phosphate buffer of the pH7.2 of 1.0mL suspends again, suspension plant cream bar
Bacterium CCFM436 thallus is mixed with the artificial simulation gastric juices of the pH2.5 of 9.0mL, is incubated at 37 DEG C, respectively in beginning (0h) and 2h
When sample, carries out plate count with the casting culture of MRS agar medium, measurement viable count simultaneously calculates its survival rate.Survival
The ratio between viable count logarithm, is expressed as a percentage when rate is the viable count logarithm and 0h in culture solution 2h.
Tolerance test of the 4 lactobacillus plantarum CCFM436 of embodiment to simulated intestinal fluid
The preparation of artificial simulation intestinal juice: 6.4g/LNaHCO3, 0.239g/LKCl, 1.28g/LNaCl, 0.1% tryptose
Enzyme, 0.3% cholate pH7.2.
Take 1mL in the culture solution of the CCFM436 containing lactobacillus plantarum of artificial simulation gastric juices culture 3h, the pH6.8 with 9.0mL
Artificial simulation intestinal juice mixing, cultivate at 37 DEG C, sampled respectively when culture starts (0h) and 5h, with MRS agar medium
Casting culture carries out plate count, measures viable count and calculates its survival rate.Viable bacteria when survival rate is culture solution 5h
The ratio between number logarithm and viable count logarithm when 0h, are expressed as a percentage.
The experimental results showed that (table 1), survival rate of the lactobacillus plantarum CCFM436 in manual simulation's gastro-intestinal Fluid environment exists
90% or more, it can be seen that, lactobacillus plantarum CCFM436 bacterial strain is good to the tolerance of gastrointestinal tract environment.When the bacterial strain passes through
Host takes orally into after enteron aisle, can pass through gastric juice and the big barrier of intestinal juice two, and keep higher vigor.
Tolerance of the 1 lactobacillus plantarum CGMCC No.12470 of table to simulation gastro-intestinal Fluid
The preparation of 5 lactobacillus plantarum CCFM436 leavening of embodiment
(1) preparation of culture medium: use in terms of culture medium gross mass 87.7% water by 10% enzyme hydrolysis skimmed milk,
0.5% glucose, 1.5% tryptone and the dissolution of 0.3% yeast extract, then adjusting its pH value is 6.4, obtains culture medium；
(2) protectant preparation: protective agent system gross mass meter pastes 10% skimmed milk power, 3% glycerol, 10% malt ring
Essence, 15% trehalose, 1%L- sodium glutamate and water are mixed with protective agent；
(3) lactobacillus plantarum CCFM436 is inoculated into the cooling culture medium of sterilizing by 3% inoculum concentration of culture medium quality
In, then the stationary culture 18h at 37 DEG C, is cleaned 2-4 times with the phosphate buffer of pH7.2, and the protective agent weight is added
Outstanding thallus, makes cell concentration reach 1010CFU/mL；Again by bacteria suspension at 37 DEG C with culture 60min, freeze-drying obtains described
Fermenting agent.
Embodiment 6 prepares the cow's milk of lactobacillus plantarum CCFM436
By raw milk defatted milk in 95 DEG C of thermal sterilization 20min, 4 DEG C are subsequently cooled to, adds lactobacillus plantarum CCFM436
Leavening, raw milk defatted milk cell concentration reach 106CFU/mL or more, it is stored refrigerated at 4 DEG C, it obtains containing lactobacillus plantarum
The cow's milk of CCFM436 active constituent.
The soymilk of the preparation of embodiment 7 CCFM436 containing lactobacillus plantarum
Using soft water soaking soybean, 2h is impregnated at 80 DEG C, removes soybean skin.Soaking water is drained, adds boiling water defibrination, and
12min is kept the temperature at a temperature of higher than 80 DEG C.By 150 mesh net filtrations of obtained slurry, and be centrifuged, obtain from
Heart liquid is thick soymilk, then thick soymilk is heated to 140-150 DEG C, imports vacuum cooled room rapidly and is vacuumized, described thick
Smell substance in soymilk is discharged rapidly with steam.After vacuum outgas, its temperature is down to about 37 DEG C, is added thereto
Lactobacillus plantarum CCFM436 leavening, makes its cell concentration reach 106CFU/mL or more, it is stored refrigerated at 4 DEG C, then
To the soymilk containing lactobacillus plantarum CCFM436 active constituent of the present invention.
The beverage made of fruits or vegetables of 8 prepared product lactobacillus CCFM436 of embodiment
It squeezes the juice after selecting fresh vegetables to clean, progress flash pasteurization, the high temperature sterilization 2s at 140 DEG C of temperature, immediately
37 DEG C are cooled to, lactobacillus plantarum CCFM436 leavening is accessed, cell concentration in juice is made to reach 106CFU/mL or more,
It is stored refrigerated at 4 DEG C, obtain the beverage made of fruits or vegetables of the active constituent of CCFM436 containing lactobacillus plantarum.
The capsule product of the preparation active constituent of CCFM436 containing lactobacillus plantarum of embodiment 9
Lactobacillus plantarum CCFM436 is cultivated into 18h in MRS culture medium, 5000rpm is collected after being centrifuged 10min at 4 DEG C
Thallus, with the phosphate buffer of pH7.2 by cell washing twice, being resuspended with skimmed milk thallus and makes lactobacillus plantarum
The final cell concentration of CCFM436 reaches 1 × 1010-3×1010CFU/mL.Bacteria suspension is added to 3% sodium alginate soln
In, it is sufficiently stirred, is dispersed in it in sodium alginate soln, then squeeze the mixed liquor to 2% calcium chloride solution
Middle formation micelle stands solidification 30min, micelle is collected by filtration, and will collect obtained micelle and carries out freeze-drying 48h, is contained
The pulvis of lactobacillus plantarum CCFM436 active constituent.Above-mentioned pulvis is fitted into capsule for medicine, the capsule product is obtained.
The acidified milk of the preparation active constituent of CCFM436 containing lactobacillus plantarum of embodiment 10
After fresh milk sugaring dissolution, 65 DEG C with carry out homogeneous under 20MPa, insulated sterilizing 5min, temperature is dropped at 95 DEG C
To 35 DEG C, lactobacillus plantarum CCFM436, business dry powder leaven lactobacillus bulgaricus and quotient are added with the mass ratio of 1:1:1
Industry dry powder leaven streptococcus thermophilus forms Mixed Microbes, and the inoculum concentration of the Mixed Microbes is the 0.03% of Milk quality, and mixing is equal
After even, the heat-preservation fermentation at 35 DEG C.After curdled milk, is refrigerated at 4 DEG C and obtain the acidified milk for 24 hours.
The tablet of the preparation active constituent of CCFM436 containing lactobacillus plantarum of embodiment 11
25.7 parts by weight of lactobacillus plantarum CCFM436 bacterium powder preparation using freeze-drying method preparation are weighed respectively, are formed sediment
55.0 parts by weight of powder, 4.5 parts by weight of cellulose derivative, 12.0 parts by weight of sodium carboxymethyl starch, 0.8 parts by weight of talcum powder, sugarcane
Wet granular is made using conventional method after evenly mixing in sugared 1.0 parts by weight and water parts by weight, carries out tabletting using tablet press machine, so
It is dried afterwards using small drug drying machine, then packs and tablet of the invention can be obtained.
The pill of the preparation active constituent of CCFM436 containing lactobacillus plantarum of embodiment 12
32.2 weight of lactobacillus plantarum CCFM436 bacterium powder preparation of the present invention prepared using freeze-drying method is weighed respectively
Part, 48.0 parts by weight of microcrystalline cellulose, 4.5 parts by weight of polyvinylpyrrolidone, 10.0 parts by weight of calcium carbonate, magnesium stearate 2.8
1.2 parts by weight of parts by weight, 1.3 parts by weight of lecithin and ethyl alcohol.After evenly mixing, this hair is made in the refined honey for adding convention amount
Bright pill.
Although the present invention has been described by way of example and in terms of the preferred embodiments, it is not intended to limit the invention, any to be familiar with this skill
The people of art can do various change and modification, therefore protection model of the invention without departing from the spirit and scope of the present invention
Enclosing subject to the definition of the claims.
Claims (10)
1. a kind of lactobacillus plantarum (Lactobacillus plantarum) is preserved in China Microbiological on May 23rd, 2016
Culture presevation administration committee common micro-organisms center, preservation address are section, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3 China
Institute of microbiology, institute, deposit number are CGMCC No.12470.
2. application of the lactobacillus plantarum described in claim 1 in the drug that preparation has row's manganese function.
3. application according to claim 2, which is characterized in that the pharmaceutical composition be by lactobacillus plantarum microbial inoculum with
Pharmaceutically acceptable carrier forms.
4. application according to claim 3, which is characterized in that the lactobacillus plantarum microbial inoculum is by the plant cream bar
The bacterium solution of bacterium is prepared by freeze drying process, it is made to contain 109The active plant lactobacillus of CFU/g or more.
5. application according to claim 4, which is characterized in that the pharmaceutically acceptable carrier is pharmaceutically to allow to make
One of filler, adhesive, wetting agent, disintegrating agent, lubricant or corrigent or its two or more combination.
6. application according to claim 3, which is characterized in that the pharmaceutical composition is granule, capsule, piece
Agent, pill and oral solutions.
7. lactobacillus plantarum described in claim 1 is preparing the application in fermented food.
8. application according to claim 7, which is characterized in that the fermented food is to use to contain the plant cream bar
Dairy products, bean product or the fruit and vegetable product of the leavening production of bacterium.
9. application according to claim 8, which is characterized in that the leavening the preparation method comprises the following steps: by claim 1 institute
It states lactobacillus plantarum and is seeded to culture medium and cultivated, addition protective agent makes cell concentration reach 1010CFU/mL is simultaneously carried out
Freeze-drying.
10. application according to claim 8, which is characterized in that the preparation method of the leavening is specifically: (1) fermenting
The preparation of culture medium: use in terms of culture medium gross mass 87.7% water by 10% enzyme hydrolysis skimmed milk, 0.5% glucose,
1.5% tryptone and the dissolution of 0.3% yeast extract, adjusting pH value is 6.4, obtains culture medium；(2) protectant preparation: with
Protective agent system gross mass meter is by 10% skimmed milk power, 3% glycerol, 10% malt cyclodextrin, 15% trehalose, 1%L-
Sodium glutamate and water are mixed with protective agent；(3) lactobacillus plantarum is inoculated into sterilizing cooling according to the 2-5% of culture medium quality
In fermentation medium, then the stationary culture 18h at 37 DEG C, is cleaned 2-4 times with the phosphate buffer of pH7.2, described in addition
Protective agent be resuspended thallus, so that cell concentration is reached 1010CFU/mL；Again by bacteria suspension in 37 DEG C of culture 60min, freeze-drying is obtained
Obtain the fermenting agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610562884.9A CN105969700B (en) | 2016-07-15 | 2016-07-15 | A kind of lactobacillus plantarum and its application with absorption manganese ion function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610562884.9A CN105969700B (en) | 2016-07-15 | 2016-07-15 | A kind of lactobacillus plantarum and its application with absorption manganese ion function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105969700A CN105969700A (en) | 2016-09-28 |
| CN105969700B true CN105969700B (en) | 2019-05-17 |
Family
ID=56952591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610562884.9A Active CN105969700B (en) | 2016-07-15 | 2016-07-15 | A kind of lactobacillus plantarum and its application with absorption manganese ion function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105969700B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107699503B (en) * | 2017-11-22 | 2020-06-09 | 内蒙古农业大学 | Abnormal yeast Weikehan yeast BT-1-1 and application thereof |
| CN107988123B (en) * | 2018-01-17 | 2021-03-02 | 江南大学 | Lactobacillus plantarum capable of regulating ampicillin-induced intestinal flora disorder |
| EP3780962A2 (en) * | 2018-04-19 | 2021-02-24 | Chr. Hansen A/S | Inhibition of fungal growth by manganese depletion |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102586148A (en) * | 2012-02-28 | 2012-07-18 | 江南大学 | Plant lactobacillus capable of relieving lead toxicity and application thereof |
| CN103756926A (en) * | 2013-11-05 | 2014-04-30 | 江南大学 | Lactobacillus plantarum capable of alleviating copper toxicity and purpose thereof |
| CN104611278A (en) * | 2015-02-27 | 2015-05-13 | 江南大学 | Lactobacillus plantarum capable of alleviating aluminum toxicity and use of lactobacillus plantarum |
-
2016
- 2016-07-15 CN CN201610562884.9A patent/CN105969700B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102586148A (en) * | 2012-02-28 | 2012-07-18 | 江南大学 | Plant lactobacillus capable of relieving lead toxicity and application thereof |
| CN103756926A (en) * | 2013-11-05 | 2014-04-30 | 江南大学 | Lactobacillus plantarum capable of alleviating copper toxicity and purpose thereof |
| CN104611278A (en) * | 2015-02-27 | 2015-05-13 | 江南大学 | Lactobacillus plantarum capable of alleviating aluminum toxicity and use of lactobacillus plantarum |
Non-Patent Citations (2)
| Title |
|---|
| 具有缓解重金属毒性作用的乳酸菌研究;翟齐啸;《乳酸菌与营养健康:第九届乳酸菌与健康国际研讨会摘要汇编 》;20140521;摘要 * |
| 耐受重金属铜的乳酸菌的筛选及其铜结合性能的研究;倪奕弘;《万方学位论文数据库》;20141119;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105969700A (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102586148B (en) | Plant lactobacillus capable of relieving lead toxicity and application thereof | |
| CN102827796B (en) | Lactobacillus plantarum with cadmium removing function and usage thereof | |
| CN104830731B (en) | One strain has plant lactobacillus AB-1 and the application thereof of broad-spectrum antibacterial characteristic | |
| CN102533618B (en) | Lactobacillus plantarum CCFM8724 and application thereof | |
| CN102174450B (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof | |
| CN105779350B (en) | A kind of lactobacillus plantarum and application thereof of anti-Bacterium enteritidis infection | |
| CN100519738C (en) | Bifidobacteria viable bacteria preparation and special-purpose protective agent thereof | |
| CN106834187A (en) | A kind of bifidobacterium bifidum and application thereof | |
| CN110141585A (en) | A kind of composite probiotics ferment microbial inoculum and preparation method thereof for adjusting intestinal flora | |
| CN104789511B (en) | One strain has plant lactobacillus AB-2 and the application thereof of broad-spectrum antibacterial characteristic | |
| CN109628358A (en) | A kind of compound probiotic and its application | |
| CN103756926B (en) | A kind of can the plant lactobacillus alleviating Copper electrodissolution and uses thereof | |
| CN101139557A (en) | Lactobacillus casei and its application for improvement of blood lipid metabolism and immunological regulation | |
| CN112056399A (en) | Probiotic composition for enhancing immunity and application thereof | |
| CN108004155A (en) | Lactobacillus plantarum pc-26 bacterial strains and its application | |
| CN109957530A (en) | A kind of lactobacillus plantarum and its application | |
| CN105969700B (en) | A kind of lactobacillus plantarum and its application with absorption manganese ion function | |
| CN104611278B (en) | It is a kind of to alleviate Lactobacillus plantarum of aluminium toxicity and application thereof | |
| CN104611256B (en) | A kind of microorganism lyophilized formulations and preparation method thereof | |
| CN107319567A (en) | It is a kind of to promote the compound probiotic chewable tablets of Instestinal motility | |
| CN106955335A (en) | It is a kind of to prevent Chinese medicine microecological preparation of calf diarrhea and preparation method thereof | |
| CN104430847A (en) | Lactobacillus fermentum Lee working leavening agent product and constipation-prevention and health application thereof | |
| CN104381440A (en) | Lactobacillus fermentum Lee working fermenting agent product and application thereof to prevent constipation and keep healthy | |
| CN111000247B (en) | Preparation method of composite probiotic powder | |
| CN104830730B (en) | One strain has Lactobacillus plantarum AB-4 and the application thereof of anti-Fructus Melo Fusarium oxysporum and anti-Fructus Melo phytophthora activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |